Viridian Therapeutics, Inc. Common Stock
Market Cap
1.8B
Short interest (May 15)
13.8%
Net Short (Jun 03 ): 0.1%
Borrow Fee
0.40%
↓ 1.2%
Available Shares
700K
↓ 39.5%
Price Chart
Company Overview
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.